TW209864B - - Google Patents

Download PDF

Info

Publication number
TW209864B
TW209864B TW081102843A TW81102843A TW209864B TW 209864 B TW209864 B TW 209864B TW 081102843 A TW081102843 A TW 081102843A TW 81102843 A TW81102843 A TW 81102843A TW 209864 B TW209864 B TW 209864B
Authority
TW
Taiwan
Prior art keywords
derivative
benzyl
pyridyl
item
tetrahydro
Prior art date
Application number
TW081102843A
Other languages
English (en)
Chinese (zh)
Original Assignee
Takeda Pharm Industry Co Ltd
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13672917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW209864(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharm Industry Co Ltd, Upjohn Co filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW209864B publication Critical patent/TW209864B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Graft Or Block Polymers (AREA)
  • Photoreceptors In Electrophotography (AREA)
TW081102843A 1991-04-11 1992-04-11 TW209864B (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7883691 1991-04-11

Publications (1)

Publication Number Publication Date
TW209864B true TW209864B (https=) 1993-07-21

Family

ID=13672917

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081102843A TW209864B (https=) 1991-04-11 1992-04-11

Country Status (19)

Country Link
EP (1) EP0579733B1 (https=)
JP (1) JP3176694B2 (https=)
KR (1) KR100249988B1 (https=)
AT (1) ATE202352T1 (https=)
AU (1) AU1743292A (https=)
CA (1) CA2106967C (https=)
CZ (1) CZ196693A3 (https=)
DE (1) DE69231886T2 (https=)
DK (1) DK0579733T3 (https=)
ES (1) ES2161692T3 (https=)
FI (1) FI934426L (https=)
GR (1) GR3036623T3 (https=)
HU (1) HUT68370A (https=)
MX (1) MX9201637A (https=)
NO (1) NO933615L (https=)
PT (1) PT100366A (https=)
SK (1) SK109993A3 (https=)
TW (1) TW209864B (https=)
WO (1) WO1992018501A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022445A1 (en) * 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
TW268952B (https=) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
BR9810142A (pt) 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
DE20119200U1 (de) 2001-11-27 2003-04-10 Joh. Winklhofer & Söhne GmbH und Co KG, 81369 München Kettenspanner mit mechanischer Verriegelung
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
KR100646128B1 (ko) 2005-04-21 2006-11-14 전라옥 ＰＰＡＲγ에 선택적으로 작용하는 테트라하이드로퀴놀린계열 티아졸리딘디온 유도체 및 그 합성방법
JP2009530293A (ja) * 2006-03-16 2009-08-27 メタボリック ソリューションズ ディベロップメント カンパニー チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
AU2013200104B2 (en) * 2006-03-16 2014-05-15 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
PL2001468T3 (pl) * 2006-03-16 2013-03-29 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
NZ571870A (en) * 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2008038359A1 (en) 2006-09-28 2008-04-03 Daido Kogyo Co., Ltd. Chain tensioner
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
KR101537830B1 (ko) 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
KR20120107493A (ko) * 2009-12-15 2012-10-02 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
US20130211095A1 (en) * 2010-04-19 2013-08-15 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
MX2012012092A (es) * 2010-04-19 2012-12-17 Metabolic Solutions Dev Co Llc Sintesis novedosa para compuestos de tiazolidinadiona.
PL2603498T3 (pl) 2010-08-10 2017-06-30 Octeta Therapeutics, Llc Nowa synteza związków tiazolidynodionu
US8895748B2 (en) * 2010-08-10 2014-11-25 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2014152843A1 (en) * 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EA202091120A3 (ru) * 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
JP7040798B2 (ja) * 2016-12-01 2022-03-23 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
ES2926580T3 (es) * 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales

Also Published As

Publication number Publication date
EP0579733A1 (en) 1994-01-26
FI934426A0 (fi) 1993-10-08
HUT68370A (en) 1995-06-28
FI934426A7 (fi) 1993-10-08
DE69231886D1 (de) 2001-07-26
CA2106967A1 (en) 1992-10-12
CZ196693A3 (en) 1994-05-18
NO933615D0 (no) 1993-10-08
WO1992018501A1 (en) 1992-10-29
MX9201637A (es) 1993-08-01
FI934426L (fi) 1993-10-08
DE69231886T2 (de) 2002-03-28
KR100249988B1 (ko) 2000-04-01
AU1743292A (en) 1992-11-17
DK0579733T3 (da) 2001-10-15
ES2161692T3 (es) 2001-12-16
GR3036623T3 (en) 2001-12-31
SK109993A3 (en) 1994-12-07
JPH0586057A (ja) 1993-04-06
JP3176694B2 (ja) 2001-06-18
EP0579733B1 (en) 2001-06-20
NO933615L (no) 1993-10-08
CA2106967C (en) 2003-12-09
PT100366A (pt) 1993-06-30
ATE202352T1 (de) 2001-07-15

Similar Documents

Publication Publication Date Title
TW209864B (https=)
TWI892960B (zh) 胺基酸化合物及使用方法
JP7611893B2 (ja) 非ペプチドソマトスタチン５型受容体アゴニストおよびその使用
ES2791315T3 (es) Agonistas triazoles del receptor APJ
JP7097358B2 (ja) アルファｖインテグリン阻害剤としての３－置換プロピオン酸
JP7835895B2 (ja) Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
JP6423372B2 (ja) 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
JP7745630B2 (ja) Ｙａｐ／ｔａｚ－ｔｅａｄ腫瘍性タンパク質の阻害剤、その合成及び使用
CN106068265B (zh) 用于治疗代谢病症的二氢吡啶酮mgat2抑制剂
EP2411368A1 (fr) Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux
CN102036666A (zh) 作为硬脂酰-辅酶a去饱和酶的抑制剂的新型哌嗪衍生物
TW201103894A (en) 4-substituted pyridazinone compound and p2x7 receptor inhibitor
CN105209447A (zh) 双环[2.2.2]酸gpr120调节剂
TW393477B (en) Tetrazole derivatives, their production and use
HUE024989T2 (en) Azaindole derivatives as ABI and SRC protein kinase inhibitors
BR112018016446B1 (pt) Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos
AU2021411658B2 (en) 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof
TW202348229A (zh) 吡啶氮氧化合物的製備方法
EP3154944A2 (en) Substituted pyridinones as mgat2 inhibitors
JP6199406B2 (ja) ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物
CN111902401B (zh) 受体抑制剂、包含其的药物组合物及其用途
WO2024114730A1 (zh) 一种用于癌症治疗的药物组合物
NZ239326A (en) 3-(1,2-benzisoxazol-3-yl)-4-pyridinamine, preparation and pharmaceutical compositions thereof
US5574033A (en) Heterocyclic compound and cardiotonic agent containing the same as effective component
TW201404772A (zh) 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用